These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30095897)

  • 21. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.
    Perez DI; Gil C; Martinez A
    Med Res Rev; 2011 Nov; 31(6):924-54. PubMed ID: 20577972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redox active metals in neurodegenerative diseases.
    Acevedo K; Masaldan S; Opazo CM; Bush AI
    J Biol Inorg Chem; 2019 Dec; 24(8):1141-1157. PubMed ID: 31650248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders.
    Di Domenico F; Tramutola A; Butterfield DA
    Free Radic Biol Med; 2017 Oct; 111():253-261. PubMed ID: 27789292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AMPK in Neurodegenerative Diseases.
    Domise M; Vingtdeux V
    Exp Suppl; 2016; 107():153-177. PubMed ID: 27812980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
    Dhib-Jalbut S; Arnold DL; Cleveland DW; Fisher M; Friedlander RM; Mouradian MM; Przedborski S; Trapp BD; Wyss-Coray T; Yong VW
    J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative stress and neurotoxicity.
    Sayre LM; Perry G; Smith MA
    Chem Res Toxicol; 2008 Jan; 21(1):172-88. PubMed ID: 18052107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerium oxide nanoparticles: a 'radical' approach to neurodegenerative disease treatment.
    Naz S; Beach J; Heckert B; Tummala T; Pashchenko O; Banerjee T; Santra S
    Nanomedicine (Lond); 2017 Mar; 12(5):545-553. PubMed ID: 28181459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds.
    Khan S; Ahmad K; Alshammari EM; Adnan M; Baig MH; Lohani M; Somvanshi P; Haque S
    Biomed Res Int; 2015; 2015():379817. PubMed ID: 26064904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cells and neurodegenerative diseases.
    Hou L; Hong T
    Sci China C Life Sci; 2008 Apr; 51(4):287-94. PubMed ID: 18368305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences.
    de Andrade Teles RB; Diniz TC; Costa Pinto TC; de Oliveira Júnior RG; Gama E Silva M; de Lavor ÉM; Fernandes AWC; de Oliveira AP; de Almeida Ribeiro FPR; da Silva AAM; Cavalcante TCF; Quintans Júnior LJ; da Silva Almeida JRG
    Oxid Med Cell Longev; 2018; 2018():7043213. PubMed ID: 29861833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neurotrophins. II: therapeutic potential].
    Zazpe A; Del Río J
    Rev Med Univ Navarra; 1997; 41(3):180-4. PubMed ID: 10420924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
    Basile MS; Bramanti P; Mazzon E
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis.
    Hedera P; Lerner AJ; Castellani R; Friedland RP
    J Neurol Sci; 1995 Feb; 128(2):219-24. PubMed ID: 7738598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.
    Manoharan S; Guillemin GJ; Abiramasundari RS; Essa MM; Akbar M; Akbar MD
    Oxid Med Cell Longev; 2016; 2016():8590578. PubMed ID: 28116038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
    Matos MJ
    Future Med Chem; 2021 Aug; 13(15):1301-1309. PubMed ID: 34137271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antioxidants in central nervous system diseases: preclinical promise and translational challenges.
    Kamat CD; Gadal S; Mhatre M; Williamson KS; Pye QN; Hensley K
    J Alzheimers Dis; 2008 Nov; 15(3):473-93. PubMed ID: 18997301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of exercise on sleep in neurodegenerative disease.
    Memon AA; Coleman JJ; Amara AW
    Neurobiol Dis; 2020 Jul; 140():104859. PubMed ID: 32243913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genes and the environment in neurodegeneration.
    Coppedè F; Mancuso M; Siciliano G; Migliore L; Murri L
    Biosci Rep; 2006 Oct; 26(5):341-67. PubMed ID: 17029001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.